Spinocerebellar Ataxia Type 3 Latest Advances

Find the Latest Research About Spinocerebellar Ataxia Type 3

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1488 publications

Correction to: Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph Disease.

Correction to: Preclinical Evidence Supporting Early Initiation of Citalopram Treatment in Machado-Joseph Disease.

Journal: Molecular neurobiology
Published: August 04, 2026

Longitudinal changes in DTI-ALPS index are associated with clinical progression and brainstem atrophy in spinocerebellar ataxia type 3.

Longitudinal changes in DTI-ALPS index are associated with clinical progression and brainstem atrophy in spinocerebellar ataxia type 3.

Journal: Parkinsonism & related disorders
Published: July 09, 2026

Polyphenol-Rich Cinnamon Bud Extract Affects Ataxin-3 Aggregation and Ameliorates SCA3 Phenotypes Through a Dual Anti-Amyloidogenic and Antioxidant Mechanism.

Polyphenol-Rich Cinnamon Bud Extract Affects Ataxin-3 Aggregation and Ameliorates SCA3 Phenotypes Through a Dual Anti-Amyloidogenic and Antioxidant Mechanism.

Journal: Molecules (Basel, Switzerland)
Published: June 12, 2026

Transcriptome-guided modeling reveals insulin-related metabolic dysfunction in SCA3 mouse cerebellum.

Transcriptome-guided modeling reveals insulin-related metabolic dysfunction in SCA3 mouse cerebellum.

Journal: Brain research
Published: May 22, 2026

Twice-Daily Scrambler Therapy for a Patient With Spinocerebellar Ataxia Suffering From Refractory Neuropathic Back Pain: A Case Report.

Twice-Daily Scrambler Therapy for a Patient With Spinocerebellar Ataxia Suffering From Refractory Neuropathic Back Pain: A Case Report.

Journal: Cureus
Published: May 04, 2026

Therapeutic potential of the Nrf2 activator omaveloxolone in spinocerebellar ataxia type 3 in cellular and Drosophila models.

Therapeutic potential of the Nrf2 activator omaveloxolone in spinocerebellar ataxia type 3 in cellular and Drosophila models.

Journal: Frontiers in pharmacology
Published: May 04, 2026

Expanded ATXN3 CAG Repeat is Stable in Human Purkinje Cells.

Expanded ATXN3 CAG Repeat is Stable in Human Purkinje Cells.

Journal: Movement disorders : official journal of the Movement Disorder Society
Published: April 08, 2026

Longitudinal Dynamics of Polyglutamine-Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3.

Longitudinal Dynamics of Polyglutamine-Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3.

Journal: Movement disorders : official journal of the Movement Disorder Society
Published: March 30, 2026

Diagnostic Pitfalls in Hereditary Neurological Disorders: Machado-Joseph Disease Presenting as Charcot-Marie-Tooth Disease: A Case Report.

Diagnostic Pitfalls in Hereditary Neurological Disorders: Machado-Joseph Disease Presenting as Charcot-Marie-Tooth Disease: A Case Report.

Journal: Clinical case reports
Published: March 10, 2026

Replication analysis of the PRKN V380L (rs1801582) variant in a Japanese cohort of spinocerebellar ataxia type 3.

Replication analysis of the PRKN V380L (rs1801582) variant in a Japanese cohort of spinocerebellar ataxia type 3.

Journal: BMC neurology
Published: March 07, 2026

Establishing Sensory Neurons as Therapeutic Targets in Peripheral Neuropathy Driven by Polyglutamine Expanded Murine ATXN3.

Establishing Sensory Neurons as Therapeutic Targets in Peripheral Neuropathy Driven by Polyglutamine Expanded Murine ATXN3.

Journal: Annals of neurology
Published: March 02, 2026

Putamen Structural-Functional Decoupling as an Early-Stage Candidate Imaging Marker for Motor Severity in Spinocerebellar Ataxia Type 3.

Putamen Structural-Functional Decoupling as an Early-Stage Candidate Imaging Marker for Motor Severity in Spinocerebellar Ataxia Type 3.

Journal: Movement disorders : official journal of the Movement Disorder Society
Published: February 25, 2026
Showing 1-12 of 1,488

Last Updated: 09/26/2026